"FDA Approves Merck's Breakthrough Drug for Rare, Fatal Conditions"
The FDA has approved a new drug called sotatercept, now known as Winrevair, for the treatment of pulmonary arterial hypertension (PAH), a rare and fatal condition. The drug, manufactured by Merck, has shown promising results in clinical trials, with patients experiencing improved ability to walk and reduced risk of disease progression. While the drug has shown potential for reversing the effects of PAH, there are still unknowns and potential side effects, including bleeding and dizziness. The annual cost of the medication is estimated to be around $243,000, and it will be available in specialty pharmacies by the end of April. Patients initially need to receive injections in a clinic but may eventually be able to administer the drug at home.
- FDA approves new drug that may help stop and even reverse a rare, fatal condition that doctors call a ‘ticking time bomb’ CNN
- FDA approves Merck's drug for rare, deadly lung condition CNBC
- Merck’s (MRK) Winrevair for Rare High Blood Pressure Disorder Approved by FDA Bloomberg
- Readout Newsletter: Merck, Vertex, and Viking updates STAT
- Merck's $11.5 Billion Bet on Its Next Big Drug Finally Arrives The Wall Street Journal
Reading Insights
0
1
11 min
vs 12 min read
95%
2,300 → 120 words
Want the full story? Read the original article
Read on CNN